A panel of 10 sleep experts studied 20 common sleep myths and found little or no evidence in support of these beliefs.
Sleep issues are highly prevalent among US adults, but few admit to it or do anything to manage it.
Dr. John Cush RheumNow
7 years 6 months ago
RCT of 63 knee OA pts - given PBO or 40 g/d freeze-dried blueberry powder x 4 mos. Significant improvement in WOMAC total, Pain scoresand ADL scores in the blueberry group, but no change in TNFα,IL-1β, IL-6, IL-10, IL-13, MMP3, MMP-13, MCP-1 levels. https://t.co/wHzCJDOuiJ
RheumNow Live Preview with Dr. Len Calabrese - Empathy
Preview of Dr. Len Calabrese's lecture on empathy at the 2019 RheumNow Live meeting.
Mike Putman EBRheum
7 years 6 months ago
Nice quick read on periop RA management.
Suspect we’re treating the surgeon more than the pt. by holding bioDMARDS, but observational data supports increased infxn risk and this algorithm seems reasonable
Most of this applies to other rheum dx as well
https://t.co/it6CqdKmTo https://t.co/UFe1mB2vhs
Dr. John Cush RheumNow
7 years 6 months ago
What is your best therapy when treating calcinosis cutis? (or write in your Rx)
jules doc__wils
7 years 6 months ago
Why 👏🏼are 👏🏼people👏🏼so👏🏼mean👏🏼to👏🏼each👏🏼other👏🏼in👏🏼medicine👏🏼??? We are on the same team. Sincerely, an extremely polite Intern 👩⚕️
Mike Putman EBRheum
7 years 6 months ago
Namilumab (mono ab to GM-CSF, Granulocyte-macrophage colony-stimulating factor) with good efficacy among MTX/TNF inadequate responders in a phase II RCT.
NNT = 3-4 at week 12 for ACR50 at max dose. Some respiratory ADE but nothing major.
https://t.co/hwHDFqCqOq https://t.co/XPsc4fjsXx
Dr. John Cush RheumNow
7 years 6 months ago
Kuddos to Philip! https://t.co/WC1EcPcz4J
RheumNow Live Preview with Dr. Richard Furie
Preview of Dr. Furie's lecture on Lupus Therapeutics: Novel Strategies to Improve Outcomes at the 2019 RheumNow Live meeting.
Dr. John Cush RheumNow
7 years 6 months ago
RheumNow Podcast is Up! Eat Your Veggies and more about drug prices, gout, tapering, PSS mortality, insoles, Temporal arter bx & more. https://t.co/3gmVISUv9E or listen to the podcast on iTunes or SoundCloud here>> https://t.co/URNYnLd7Yi
JAMA Dermatology reports that patients with hidradenitis suppurativa have significantly more comorbidities than do patients with psoriasis.
A cross-sectional study compared 5306 HS patients, 14 037 patients with psoriasis, and 1 733 810 controls from electronic health records between 2013 and 2018. Specifically they examined comorbidities using the Charlson Comorbidity Index (CCI) score.
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Dr. John Cush RheumNow
7 years 6 months ago
Meet The Lancet Rheumatology: Advisory Board https://t.co/fA0siCsQbX
Dr. John Cush RheumNow
7 years 6 months ago
Phase 3 study tanezumab (anti-NGF) 2.5 mg or 5 mgin knee or hip OA find that 5 mg met 2/3 of 3 primary endpoints at 16wks; but the lower dose failed to be superior to NSAIDs in this 1 yr study. Safety outcomes where less favorable w/ tanezumab. https://t.co/l4Qffdn1nl
